To the best of our knowledge, this is the first study to report anti-PD-1 plus targeted therapy for unresectable or advanced HCC patients with Child-Pugh B liver function in real-world clinical practice, which will provide an alternative treatment option for this population, especially in China and Southeast Asia, where HBV is highly prevalent. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.